- Report
- December 2022
- 92 Pages
North America
From €1314EUR$1,500USD£1,140GBP
- Report
- December 2022
- 108 Pages
Europe
From €1314EUR$1,500USD£1,140GBP
- Report
- August 2024
- 140 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- January 2024
- 146 Pages
Global
From €3722EUR$4,250USD£3,231GBP
- Report
- February 2024
- 179 Pages
Global
From €2627EUR$3,000USD£2,280GBP
- Report
- January 2024
- 118 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2023
- 115 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- July 2023
- 115 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- October 2024
- 200 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- June 2024
- 120 Pages
North America
From €3389EUR$3,869USD£2,941GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3389EUR$3,869USD£2,941GBP
- Report
- June 2024
- 140 Pages
Europe
From €3389EUR$3,869USD£2,941GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3389EUR$3,869USD£2,941GBP
- Report
- April 2024
- 140 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- June 2023
- 140 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- May 2023
- 140 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- May 2023
- 147 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- April 2025
- 137 Pages
From €3022EUR$3,450USD£2,623GBP
- Report
- July 2024
- 108 Pages
North America
From €3022EUR$3,450USD£2,623GBP
- Report
- July 2024
- 112 Pages
Europe
From €3022EUR$3,450USD£2,623GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more